CMS plans to end CME Sunshine exemption

Share this article:
Data Management: Sunshine on My Shoulders
CMS plans to end CME Sunshine exemption

The Centers for Medicare & Medicaid Services, in what amounts to a sudden about face, wants to delete the Sunshine rule's exclusion for continuing medical education.

The elimination of the exemption, a U-turn after earlier granting such payments a carve-out, was among several intended changes to the Open Payments program included in the proposed Physician Fee Schedule for Calendar Year 2015.

While it might seem that this policy change could compel industry to report payments to physicians for CME, the proposal does not appear to affect the statutory exclusion of “indirect” payments, which, according to a note from industry trade group Coalition for Healthcare Communication (CHC), is a provision which excludes payments or other transfers of value where the applicable manufacturer is unaware of the identity of the covered recipient.

The exclusion of indirect payments is one of three conditions outlined in the Sunshine Act to exempt payments to faculty or speakers. The other two are that payments must relate to an accredited event, and that manufacturers cannot select speakers. Payments that meet those three criteria are not now required to be collected by pharma and medical device companies.

The CMS, just prior to the July 4 holiday weekend, explained its rationale for the change as follows: “Eliminating the exemption for payments to speakers at certain accredited or certifying continuing medical education events will create a more consistent reporting requirement, and will also be more consistent for consumers who will ultimately have access to the reported data."

According to the proposal, “CMS's apparent endorsement or support to organizations sponsoring continuing education events was an unintended consequence of the final rule.”

CME's Sunshine carve-out could also have enabled drug and device makers to evade disclosure by shifting their promotional budgets to CME and away from direct promotional programs, asserted Modern Healthcare in a recent piece that quoted Daniel Carlat, of the Prescription Project at Pew Charitable Trusts, as saying that continuing education programs lead physicians “to unduly prescribe products that industry is pushing.”

The proposed rule will be published in the Federal Register on July 11, and CMS will accept comments until Sept. 2. In the meantime, medical communications companies and industry appear to have been taken off guard but are mounting “a sharp and effective defense of the CME exemption,” wrote the CHC.

The CHC called the proposal “a huge step back in reasonable enforcement of the Sunshine Act,” adding that it's working with industry and lobbying partners, including the CME Coalition and the Alliance for CME in the Health Professions, to develop the response. 

"We are stunned that CMS would reverse course on the common sense reporting exemption for accredited CME that they, themselves, created and finalized last year,” wrote Andrew Rosenberg, senior advisor to the CME Coalition.

“If it is allowed to stand,” Rosenberg added, “this policy change will be highly disruptive to every stakeholder in the CME ecosystem—doctors, educators and commercial supporters—who have spent over a year preparing for the implementation of the current rules. We are at a loss to explain why CMS would abruptly reverse its own Final Rule which came as a result of significant stakeholder input and participation from all sides.

“CMS got it right the first time when it recognized that encouraging the practice of accredited CME is vitally important for doctors and patients, and that extending the Sunshine Act's reporting requirements for direct payments between doctors and manufacturers to participants in bona fide, accredited CME would actually discourage physicians from learning new medical science by creating a false stigma of public disclosure. We will fight this proposal alongside patients, doctors and others in order to protect CME from being treated no differently from promotional, marketing or other reportable payment categories under the Sunshine Act."

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...